Linezolid for drug-resistant tuberculosis

Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J. Sloan

doi:10.1002/14651858.CD012836

Linezolid for drug-resistant tuberculosis

Bhagteshwar Singh^*
, Derek Cocker
, Hannah Ryan
, Derek J. Sloan

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.

Original language	English
Article number	CD012836
Pages (from-to)	1-9
Number of pages	9
Journal	Cochrane Database of Systematic Reviews
Volume	2017
Issue number	11
DOIs	https://doi.org/10.1002/14651858.CD012836
Publication status	Published - 10 Nov 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1002/14651858.CD012836

Handle.net

Persistent link to portal record

1 Review article

Linezolid for drug-resistant pulmonary tuberculosis
Singh, B., Cocker, D., Ryan, H. & Sloan, D. J., 20 Mar 2019, In: Cochrane Database of Systematic Reviews. 2019, 3, CD012836.
Research output: Contribution to journal › Review article › peer-review

Open Access
File

Cite this

@article{9801f6108f294037b7a8fba25b7fa137,

title = "Linezolid for drug-resistant tuberculosis",

abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.",

author = "Bhagteshwar Singh and Derek Cocker and Hannah Ryan and Sloan, \{Derek J.\}",

year = "2017",

month = nov,

day = "10",

doi = "10.1002/14651858.CD012836",

language = "English",

volume = "2017",

pages = "1--9",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "Wiley",

number = "11",

}

TY - JOUR

T1 - Linezolid for drug-resistant tuberculosis

AU - Singh, Bhagteshwar

AU - Cocker, Derek

AU - Ryan, Hannah

AU - Sloan, Derek J.

PY - 2017/11/10

Y1 - 2017/11/10

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with multidrug-resistant (MDR-) and extensively drug-resistant (XDR-) pulmonary tuberculosis (TB), and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.

U2 - 10.1002/14651858.CD012836

DO - 10.1002/14651858.CD012836

M3 - Review article

AN - SCOPUS:85033440390

SN - 1469-493X

VL - 2017

SP - 1

EP - 9

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 11

M1 - CD012836

ER -

Linezolid for drug-resistant tuberculosis

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Research output

Linezolid for drug-resistant pulmonary tuberculosis

Cite this